Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.
- Signed $2M contract with Fakeeh Care Group in Saudi Arabia
- Strategic review targets cash operating profit break-even by FY27
- Withdrawal of double-digit ARR growth guidance for FY26
- Focus on high-growth product lines and improved sales pipeline
- Contract supports pathway to future SaaS ARR sales
$2 Million Contract Win Expands Saudi Footprint
Beamtree Holdings Limited (ASX:BMT) has secured a substantial $2 million AUD contract with Fakeeh Care Group, a prominent healthcare provider operating multiple hospitals and medical centres in Saudi Arabia. The 12-month agreement, commencing in May 2026, will see Beamtree deliver clinical coding, coding assurance, and analytics services both remotely and on-site. This contract aligns with sweeping healthcare reforms in Saudi Arabia, where hospitals are adjusting clinical coding practices to enhance funding reimbursement frameworks.
This deal builds on Beamtree’s established presence in Saudi Arabia, which includes projects such as a nationwide data quality audit for the Center for National Health Insurance and a partnership with Lean Business Services launched in late 2023 to provide integrated coding solutions. While this contract is not classified as annual recurring revenue (ARR), it represents an important commercial milestone and a potential springboard for future SaaS ARR sales, consistent with Beamtree’s international growth strategy. The contract remains subject to standard termination rights for non-performance.
Strategic Review Drives Cost Discipline and Product Focus
Alongside the contract announcement, Beamtree provided an interim update on its strategic review, initiated in February 2026. The Board has moved decisively to reset the company’s cost base, targeting alignment of cash operating costs with revenue by 1 July 2026. This aims to position Beamtree towards cash operating profit break-even after product development expenses in FY27.
Beamtree’s portfolio comprises three product groups: Data Platforms (including Health Roundtable and Evolve), Coding Suite (clinical coding quality and audit), and Diagnostics (RippleDown diagnostic decision support). The Board has assessed these products by margin and growth potential, deciding to concentrate investment on the highest-growth lines while reducing or ceasing investment in underperforming areas.
To sharpen revenue predictability, Beamtree has enhanced sales pipeline disciplines. However, with just two months remaining in FY26, several active opportunities are unlikely to close before the full-year results, prompting the Board to withdraw its prior guidance of double-digit ARR growth for FY26. This marks a notable revision from the company’s earlier growth ambitions, reflecting a more cautious near-term outlook. The strategic review’s next phase will clarify product prioritisation and market development plans, to be detailed in the FY26 results announcement.
International Growth and Revenue Trajectory
Beamtree’s international expansion has been a key driver of recurring revenue growth in recent years, with prior contract wins in Singapore and the UK underpinning momentum. The $2 million Fakeeh Group contract continues this trend, complementing previous projects such as the $1 million Singapore Ministry of Health audit contract awarded in 2025. These international engagements exemplify Beamtree’s strategy of leveraging its proprietary coding and analytics platforms to capture new healthcare markets.
Despite the revised ARR guidance, the company remains confident in its medium-term pipeline and growth prospects. The strategic review and cost realignment signal a disciplined approach to balancing investment with financial sustainability. Investors will be watching closely for the FY26 full-year results, which will provide more clarity on Beamtree’s product roadmap and the impact of its Saudi contract on recurring revenue streams.
Beamtree’s Executive Chair Emma Gray authorised the release, underscoring the company’s commitment to transparent communication as it navigates this pivotal phase.
Beamtree’s recent moves echo its earlier progress reported in February 2026, when the company highlighted a 10% increase in recurring revenue and a narrowed net loss amid strategic initiatives. The current update adds nuance to that trajectory, blending cautious near-term revenue expectations with a clear pathway to operational efficiency and international growth.
Bottom Line?
Beamtree’s $2 million Saudi contract is a bright spot amid a strategic reset that tempers near-term ARR growth expectations, setting the stage for a sharper focus on profitability and high-potential products.
Questions in the middle?
- How will Beamtree convert the Fakeeh Group contract into recurring SaaS revenue?
- Which product lines will emerge as the company’s primary growth engines post-review?
- What impact will delayed sales closures have on FY27 revenue and profitability?